Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Estrogen modulation of growth hormone secretion and hepatic fat metabolism
ACTRN12611001093976Phase 4Recruiting
- Sponsor
- Garvan Institute of Medical Research
- Start
- Aug 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of estradiol, tamoxifen and letrozole (2 arms), sponsored by Garvan Institute of Medical Research. Primary endpoints: Whole body fatty acid metabolism, Liver fatty acid metabolism and 1 more. Started Aug 2010; status: recruiting.
02
Drugs
estradioltamoxifenletrozole
Beyond the preview
Go deeper on ACTRN12611001093976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611001093976.